Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bard’s Lutonix Drug-Coated Balloon Shows Efficacy In Early Trial Results

This article was originally published in The Gray Sheet

Executive Summary

Six-month data from the rigorous Levant 2 trial, presented at the TCT conference in San Francisco, show peripheral angioplasty with Bard’s Lutonix paclitaxel-coated balloon reduces restenosis compared with regular balloon angioplasty. The findings give the company an edge in the race to be the first on the U.S. market with a drug-coated peripheral angioplasty balloon.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts